Site reactions in peripheral fosaprepitant infusions

0

To verify the incidence of infusion site reactions and the relationship among risk factors, a quantitative retrospective cohort study was undertaken” Gonçalves et al (2017).

Abstract:

Fosaprepitant is administered intravenously to treat chemotherapy-induced nausea and vomiting. To verify the incidence of infusion site reactions and the relationship among risk factors, a quantitative retrospective cohort study was undertaken. The study included patients seen between October 2013 and February 2014. Fifty-seven patients were included in the study, and there were 105 infusions among them. Infusion site reactions were identified in 42 (40%) cases. Risk factors identified by the study included age (P < .001), insertion at the back of the hand and wrist (P < .001), and first fosaprepitant administration (P < .001). The study found evidence of a higher incidence of infusion site reactions than was reported in the package insert.

Reference:

Gonçalves, S.C., Sanches, S.M., Bueno, C.T., Villela de Castro, D.L., Damascena, A. and Santos, G.R.C. (2017) Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions. Journal of Infusion Nursing. 40(6), p.380-383.

doi: 10.1097/NAN.0000000000000252.

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.